Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia - 1 May 2015

Kepa S, Horvath B, Reitter-Pfoertner S, Schemper M, Quehenberger P, Grundbichler M, Heistinger M, Neumeister P, Mannhalter C, Pabinger I

Abstract excerpt

In haemophilia A patients factor VIII (FVIII) recovery and half-life can vary substantially. There are parameters known to modulate FVIII pharmacokinetics (PK), but they explain only about 34% of the variability. The aim of this study was to identify new parameters that influence FVIII PK and thus to expand the current knowledge. FVIII PK were determined in 42 haemophilia A patients (37 severe, 5 moderate)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ABO Blood-Group System
Share to Blood Coagulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Body Mass Index

Share to Factor VIII

Share to Half-Life

Share to Hemophilia A

Share to Low Density Lipoprotein Receptor-Related Protein-1

Share to von Willebrand Factor

Source

Identifiers

PMID: 25582282
DOI: 10.1111/hae.12592

Genes

LRP1
VWF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.PMID 25582282Read ↗

Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.Semantic proximity Read ↗

[Pharmacokinetic Study of Coagulation Factor Ⅷ in Adults with Severe Hemophilia A].Semantic proximity Read ↗

Variable pharmacokinetics of coagulation factor VIII in the perioperative setting complicates personalisation of treatment in patients with haemophilia ASemantic proximity Read ↗

Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study.Semantic proximity Read ↗

Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients.Semantic proximity Read ↗

Extending half-life in coagulation factors: where do we stand?Semantic proximity Read ↗

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophiliaSemantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

Factor VIII inhibitors in patients with congenital severe haemophilia A and its relation to genotype.Semantic proximity Read ↗

Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A.Semantic proximity Read ↗

Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations.Semantic proximity Read ↗

Unravelling the effect of blood group on FVIII:C levels and response to DDAVP in 20 males with a single genotype (Twillingate Variant) causing Haemophilia A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.